The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Olorofim Aspergillus Infection Study (OASIS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05101187
Recruitment Status : Recruiting
First Posted : November 1, 2021
Last Update Posted : April 17, 2024
Sponsor:
Collaborators:
Iqvia Pty Ltd
Shionogi
Information provided by (Responsible Party):
F2G Biotech GmbH

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with IFD caused by proven IA or probable lower respiratory tract disease Aspergillus species (invasive aspergillosis, IA).

Condition or disease Intervention/treatment Phase
Invasive Aspergillosis Drug: Olorofim Drug: AmBisome® Phase 3

Detailed Description:

The mortality rate in immunosuppressed patients with IA is high even with effective modern antifungal drug treatment. Intrinsic and acquired resistance to azoles and amphotericin B, the two most effective classes of treatment, have been identified in Aspergillus species and are linked to this increased mortality.

Currently marketed antifungal drugs have limitations including limited dosage forms, DDIs, and significant adverse reactions.

For patients with IA who do not respond to or cannot tolerate a triazole therapy, treatment options are even more limited.

Olorofim is an antifungal candidate with a novel mechanism of action offering activity against resistant organisms, differences in safety profile, along with oral dosing, predictable and reliable pharmacokinetic (PK) profile and limited potential for DDIs.

The present study is designed to compare the efficacy, safety, and tolerability of olorofim with that of AmBisome® followed by guideline-based hierarchy standard of care (SOC) in patients with IA whose infection is either refractory to or unsuitable for azole therapy.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 225 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Masking Description: Adjudicator and sponsor-blinded.
Primary Purpose: Treatment
Official Title: Phase III, Adjudicator-blinded, Randomised Study to Evaluate Efficacy and Safety of Treatment With Olorofim Versus Treatment With AmBisome® Followed by Standard of Care in Patients With Invasive Fungal Disease Caused by Aspergillus Species
Actual Study Start Date : March 31, 2022
Estimated Primary Completion Date : September 14, 2024
Estimated Study Completion Date : November 1, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Aspergillosis

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Olorofim
Olorofim versus AmBisome followed by Standard of Care (SOC)
 Drug: Olorofim
Loading Dose: 5 tablets (150 mg) to be taken twice daily at a 12-hour (± 1 hour) interval on Day 1 Maintenance Dose: 3 tablets (90 mg) to be taken twice daily at 12-hour (± 1 hour) intervals from Day 2 until Day 84 (± 7 days)
Other Name: Olorofim (F901318)
Active Comparator: AmBisome
Olorofim versus AmBisome followed by Standard of Care (SOC)
 Drug: AmBisome®
Initial course of at least 10 days of AmBisome® administered daily at a dose of 3 mg/kg by IV infusion over a 30- to 60-minute period or according to local guidelines Administration of SOC will follow international, national, or local guidelines and product labelling.
Other Name: AmBisome® (liposomal amphotericin B)


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. All-cause mortality [ Time Frame: Treatment Day 42 ]
    To compare all-cause mortality (ACM) at Day 42 following treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in the intent-to-treat (ITT) population of patients with Invasive Fungal Disease (IFD) caused by proven Invasive Aspergillosis (IA) at any site or probable lower respiratory tract disease (LRTD) Aspergillus species (invasive aspergillosis, IA).


Secondary Outcome Measures :
  1. Adjudicated Assessment of Overall outcome [ Time Frame: Day 42, Day 84, and End of Treatment (anytime during the study between first administration and Day 84) ]
    To compare the effects of treatment with olorofim versus treatment with AmBisome® followed by SOC on Data Review Committee (DRC)-adjudicated assessment of overall outcome in patients with proven IA or probable LRTD IA at Day 42, Day 84, and End of Treatment.

  2. Investigator-assessed overall response [ Time Frame: Day 14, Day 28, Day 42, Day 84, EOT (End of Treatment - Maximum Treatment 84 days [± 7 Days]), and 4-week Follow-up (FU). ]
    Investigator-assessed overall response (integrating clinical, radiological, and mycological response).

  3. To compare the effects of treatment with olorofim versus treatment with AmBisome® followed by SOC on Galactomannan index. [ Time Frame: Day 14, Day 28, Day 42, Day 84, EOT (End of Treatment - Maximum Treatment 84 days [± 7 Days]) and 4-week Follow-up (FU) ]

    The Sponsor's expert advisors suggested that an appropriate rule would be a failure of the GM to decline from baseline. The experts also state that they have seen very significant variation on retesting of both BAL and serum GM samples and believe it is more appropriate to state a fixed reduction of ≥ 1.0 units than any percentage reduction.

    These rules are used for changes in GM that document failure of therapy:

    1. Serum: After 8 or more days of treatment, serum GM has neither (1) fallen by ≥ 1 unit nor (2) to < 0.5 based on measurements taken at least 8 days apart.
    2. BAL: After 8 or more days of treatment, positive GM from BAL in a patient with a previous BAL test that did not meet the definition of positive (too low or entirely negative) without regard for the interval of time between samples.

  4. To collect additional olorofim and the disproportionate metabolite H26C pharmacokinetic (PK) data for inclusion in a Population PK model [ Time Frame: Day 10, Day 14, Day 21, Day 28, Day 42, Day 56, Day 70, Day 84, and at EOT (End of Treatment - Maximum Treatment 84 days [± 7 Days]) ]
    To collect plasma concentration of olorofim and H26C metabolic for for PK analysis (pre-dose and intensive PK). No non-compartmental PK analysis will be performed on the data relating to pre-dose samples and intensive PK samples, apart from data collected from selected regions, which will be reported separately. All relevant olorofim data will be provided to support population PK modelling, which will be reported separately.

  5. Data Review Committee's Assessment of Patient Mortality [ Time Frame: Day 42 and 84 and EOT (End of Treatment - Maximum Treatment 84 days [± 7 Days]) ]
    Study data will be independently assessed by a blinded DRC consisting of independent experts in the diagnosis and management of IA, providing an independent adjudication of each patient's mortality based on the survival status collect at time frame.

  6. Diagnosis of a secondary fungal infection [ Time Frame: at any time through End Of Treatment ]
    To compare incidence of a secondary fungal infection when patients treated with olorofim versus treatment with AmBisome followed by SOC.

  7. Quality of life as measured by the 5 Level 5 Dimension (EQ-5D-5L) at Baseline [ Time Frame: Days 14 and EOT (End of Treatment - Maximum Treatment 84 days [± 7 Days]) ]
    To assess patient's quality of life measured by the 5-Level 5-Dimension EuroQol Group Health-related Quality of Life Questionnaire (EQ-5D-5L) in both treatment groups

  8. Survival status [ Time Frame: Day 42, Day 84, and End Of Treatment and at the 4 weeks ± 7 days FU ]
    All-cause mortality will be assessed using survival status at time frame.

  9. Safety Assessment [ Time Frame: up to the Day 84 and 4-week Follow-up (FU) ]
    To monitor incidence of Adverse Events and Serious Adverse Events in both treatment arms (Olorofim or AmBisome followed by Standard of Care).


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female patients ages over 18 years and weighing more than 30 kg
  2. Patients with proven IA at any site or probable LRTD IA per EORTC/MSG 2019 criteria as adapted for this study and where the duration of specific therapy for this episode of IA has been ≤ 28 days. For purposes of this inclusion, the duration of specific therapy includes any mould-active therapy given for this episode of IA whether subsequently judged potentially effective or not.
  3. Patients requiring therapy with an antifungal agent other than a mould-active azole, and who have had ≤ 96 hours of potentially effective prior therapy. Potentially effective prior therapy includes any agent to which the infecting strain of Aspergillus is likely to be susceptible. There are no exclusions or limitations on such agents (eg, AmBisome® is permitted) other than their duration.
  4. AmBisome® is an appropriate therapy for the patient.

Exclusion Criteria:

  1. Women who are pregnant or breastfeeding.
  2. Known history of allergy, hypersensitivity, or any serious reaction to any component of the study drug
  3. Patients with only chronic aspergillosis, aspergilloma, or allergic bronchopulmonary aspergillosis.
  4. Suspected mucormycosis (zygomycosis).
  5. Patients with a known active second fungal infection of any type, other than candidiasis that can be treated with fluconazole.
  6. The requirement for ongoing use of echinocandin as Candida prophylaxis.
  7. Microbiological findings (eg, bacteriological, virological) or other potential conditions that are temporally related and suggest a different aetiology for the clinical features.
  8. Human immunodeficiency virus (HIV) infection but not currently receiving antiretroviral therapy.
  9. Patients with a baseline prolongation of QT using Fridericia's Correction Formula (QTcF) ≥ 500 msec, or at high risk for QT/QTc prolongation.
  10. Evidence of hepatic dysfunction.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05101187


Contacts
Layout table for location contacts
Contact: Daniela Zinzi, MD +43 06643582281 DZinzi@f2g.com

Locations
Show Show 101 study locations
Sponsors and Collaborators
F2G Biotech GmbH
Iqvia Pty Ltd
Shionogi
Investigators
Layout table for investigator information
Principal Investigator: Johan Maertens, MD UZ Leuven
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: F2G Biotech GmbH
ClinicalTrials.gov Identifier: NCT05101187    
Other Study ID Numbers: F901318/0041
First Posted: November 1, 2021    Key Record Dates
Last Update Posted: April 17, 2024
Last Verified: April 2024

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by F2G Biotech GmbH:
Invasive fungal disease (IFD)
Aspergillus species
Olorofim
Non-azole antifungal
Azole resistance
Additional relevant MeSH terms:
Layout table for MeSH terms
Aspergillosis
Mycoses
Bacterial Infections and Mycoses
Infections
Amphotericin B
Liposomal amphotericin B
Olorofim
 Amebicides
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Anti-Bacterial Agents
Antifungal Agents